Parental Depression Has an Impact on Treatment Adherence in Children with Exocrine Pancreatic Insufficiency

Article

A new study suggests that caregivers who want to increase the use of pancreatic enzymes by young patients with cystic fibrosis should consider whether their parents need treatment for depression.

A new study suggests that caregivers who want to increase the use of pancreatic enzymes by young patients with cystic fibrosis should consider whether their parents need treatment for depression.

Investigators used the Center for Epidemiologic Studies Depression Scale (CES-D) to gage how parental mood affected treatment adherence and weight change over a 3-month period in 83 patients aged 1 to 13 years.

Overall adherence to pancreatic enzyme regimens was 49.4% ± 3.4%. Subset analysis found that adherence was higher at school (94.4% ± 6.1%) than at home (42.3% ± 3.1%), and that it was higher for toddlers (50.6% ± 5.2%) than for school-aged children (37.5% ± 3.7%).

Nearly half of all parents reported significant depressive symptoms. Some 30% of them scored in the “clinical” range on the CES-D, and another 18% scored in the scale’s “moderate” range.

Subsequent analysis found that parental depression was associated with juvenile use of pancreatic enzyme supplements. Adherence rates were lower among children whose parents showed signs of depression (34.8% ± 4.5%) than they were among other children (48.5% ± 4.1%).

Adherence to enzyme treatment, moreover, had a significant effect on 3-month weight gain.

“Average gain in weight z scores across 3 months was 0.5 ± 0.2 for children who were >50% adherent and —0.1 ± 6.1 for children who were <33% adherent. Parental depression had a significant, indirect effect on weight via adherence (–0.005 ± 0.003 gain in weight z score per CES-D unit),” the investigators wrote in Pediatrics.

“High rates of parental depressive symptoms, coupled with its negative effects on adherence, suggest that measuring and treating parental depression may improve children's adherence to therapy.”

The overall adherence rates reported by the new study are on the high end of adherence rates reported by other studies that have followed children and teens with cystic fibrosis. A 2006 study that appeared in the Journal of Cystic Fibrosis found that less than half of patients adhered to treatment protocols, which the investigators said was typical of chronic ailments in children.

“When examining more objective measures, rates of overall adherence were below 50% for children with cystic fibrosis, indicating generally poor adherence to the treatment regimen. For example, rates of adherence to enzyme medications, using electronic and diary measures, ranged from 27% to 46%,” the authors of that study wrote.

“Accurately measuring rates of treatment adherence for children with CF is an important step in developing effective interventions to influence these behaviors.”

Other research indicates that patients (and their parents) actually have a fairly accurate notion of how well they adhere to treatment and that the key to greater adherence lies in motivating them to increase their efforts. A small Canadian study that appeared in the Canadian Journal of Dietetic Practice and Research measured adherence among adolescents with cystic fibrosis and then compared it with perceived adherence reported by the teens.

“The adherence survey indicated that the majority perceived themselves to be adherent to taking enzymes with meals (67%), but only 44% perceived themselves to be adherent to taking enzymes with snacks,” the study authors wrote. “Recorded amounts of enzymes, taken over three days, indicated that 67% of participants were actually adherent to taking enzymes with meals and 56% with snacks.”

Related Videos
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Vipul Jairath, MBChB, DPhil | Credit: LinkedIn
Marla Dubinsky, MD | Credit: LinkedIn
Marla Dubinsky, MD | Credit: LinkedIn
Marla Dubinsky, MD | Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.